Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618267 · ClinicalTrials.gov registry record
ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 100
- Enrollment target
NCT00618267 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 100 participants.
The verdict
NCT00618267 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change certain substances (cells) found in the immune (protective) system. Blood test will be drawn by doing the following: * Use a new method called the "Immuknow®" Test to see if this method will help to better understand how MS medicines work. * Measure certain levels of immune cells in a new way, to see if it this will help to understand the body's response to MS medicines. These methods will test those with MS who are not taking any MS medications, to help us compare the results. About 100 subjects will be enrolled in this study at the Partners Multiple Sclerosis Center at Brigham and Women's Hospital. Biogen Idec, Inc. of Cambridge, MA, is paying for this study to be done.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618267
The ClinicalTrials.gov registry entry for NCT00618267 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00618267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618267 about?
NCT00618267 is a clinical study titled "ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.". The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change certain substances (cells) found in the immune (protective) system. Blood test will be drawn by doing the following...
What is the current status of trial NCT00618267?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2008-03. Estimated completion is 2008-12.
Who is sponsoring clinical trial NCT00618267?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.